NVDA, MU, AVGO & LRCX: Picking Winners in a Volatile AI Trade

Glen Smith sees a positive market outlook, citing strong earnings and historical midterm trends, while noting that high expectations make forward guidance increasingly important. He favors healthcare and financials, including JPMorgan Chase, Johnson & Johnson and UnitedHealth, and remains bullish on AI-related names Nvidia, Broadcom, Lam Research, HPE and Micron; he cautions against overconcentration and debt-heavy plays such as CoreWeave.

Analysis

Treat this as a positioning cue, not an earnings signal: the article supplies no revisions, valuation evidence or company-specific guidance. With expectations already described as high, the near-term payoff is asymmetric around forward commentary—an earnings beat without raised outlook may not sustain a rally, while cautious guidance can trigger multiple compression before estimates reset.

The AI names are not one diversified exposure. NVDA, AVGO, LRCX, MU and HPE sit at different points in the compute buildout, but a shared capex slowdown or crowded-factor unwind could hit them together. Over 6–18 months, substitution between accelerator architectures and custom silicon could redistribute spend rather than eliminate it; validate demand through order trends, utilization, memory pricing and customer capex commentary. CRWV’s debt sensitivity makes funding costs, refinancing terms and contracted utilization important downside checks, but the article alone does not establish that its balance sheet is mispriced.

JPM, JNJ and UNH may diversify AI-factor risk, not provide a guaranteed hedge: financials remain exposed to rates and credit, while healthcare outcomes can be driven by company-specific costs, regulation and litigation. Historical midterm patterns are a weak timing input versus guidance and macro data. The contrarian risk is that enthusiasm for earnings and seasonal patterns is already embedded; the opportunity is dispersion, not a blanket market or AI call.

Key Decisions for Investors

• Avoid adding broad AI exposure solely on this commentary. Into the next earnings cycle, monitor guidance revisions and customer capex alongside price action; reduce exposure if the basket rallies while forward estimates stall, or if multiple members cut demand outlooks.
• Use a conditional relative-value watch, not an unconditional pair: long a quality, cash-generative AI beneficiary against CRWV only if leverage, refinancing needs and utilization data confirm materially greater downside sensitivity at CRWV. Falsify the setup if CRWV demonstrates durable contracted utilization and improving funding terms, or if the long leg’s guidance weakens.
• For a 1–3 month lower-beta counterweight, consider a measured tilt toward JPM/JNJ/UNH versus an overweight AI basket rather than treating these names as a market hedge. Reassess on credit/rate moves, healthcare cost or regulatory updates, and company guidance; the article gives no basis for a price target.
• Keep the broad-market view near neutral until earnings guidance confirms the optimism. A sustained deterioration in forward estimates or a sharp risk-off move would outweigh the seasonal thesis; improving guidance breadth would support selectively adding exposure.